Vendor Intelligence Report: Yabang Peptide

Published 3 Jul 2026. 21-page investigative report on who is behind Yabang Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 24 Finnrick lab tests, Yabang Peptide shows a 79% overall pass rate, with 19 pass and 5 fail. The record is uneven rather than uniformly bad: GHK-Cu is the strongest current signal but rests on only two tests, while Retatrutide is the better Yabang GLP-1 line. Tirzepatide is the clearest caution, and TB-500 does not earn high confidence despite clean binary passes. The report also shows ratings shifting under stricter scoring, making batch-level verification more important than the headline percentage.

The intelligence finding behind the numbers is a provenance problem. Yabang’s storefront presents a longer manufacturing history, but B2B profiles and the domain/certificate trail point to a much younger, trading-company footprint. The visible legacy catalog centers on aesthetics supplies rather than verified peptide manufacturing, so the buyer issue is not simply real versus fake; it is whether the exact lot has independent proof.

Channel verification is also weak. The site uses shared export-site infrastructure and carries template residue: an oil-industry footer, a CGTN social meta tag, and a privacy-policy placeholder. Social icons do not resolve to verified brand profiles. Public buyer reports describe responsive WhatsApp sales, but also tracking dead zones, long shipping delays, and payment-hold friction.

Inside the full report:

  • Complete product-by-product Finnrick breakdown and methodology-divergence charts for all five tested products
  • Chronology comparing founding claims with B2B profiles, archive checks, and domain/certificate records
  • Corporate identity review of Shijiazhuang Yabang Trading Co., Ltd. and its aesthetics-supply storefronts
  • Infrastructure artifacts covering diymysite.com, bjyyb.net, shared hosting, nonfunctional social icons, and template residue
  • Buyer-logistics review from Reddit threads, including WhatsApp sales aliases, shipping-delay patterns, and Alibaba payment holds
  • X and web coupon/referral sweep showing no visible promoter network in the covered sources

Risk assessment

  • Misleading provenance and manufacturer-status risk — high: About Us claims 2015 and Global Sources claims 2007, but accessible B2B records identify Shijiazhuang Yabang Trading Co., Ltd. as a 2024 trading company and the domain/cert footprint starts 2025-09-04; peptide manufacturing is not verified.
  • Tirzepatide quality-control risk — high: Tirzepatide is Yabang’s weakest GLP-1 line: 9 tests, 6 pass / 3 fail, Finnrick rating 74.44%, with field extraction flagging a severe May 2026 batch failure.
  • Retatrutide batch-variability risk — medium: Retatrutide is stronger than Tirzepatide but not clean: 9 tests, 7 pass / 2 fail, Finnrick rating 78.72%, with a May 2026 underfill failure flagged in field extraction.
  • BPC-157 and TB-500 confidence risk — medium: Both have only 2 tests and no failures, but low current ratings — BPC-157 55.06% and TB-500 42.97% — make them weak directional choices without retesting.
  • Operational-transparency and authenticity-verification risk — medium: Template artifacts, nonfunctional social icons, free 163.com email, no verified social/reseller list/COA authentication process, and ScamAdviser/Gridinsoft trust pages at 0/100 and 16/100 impair channel verification.
  • Logistics reliability risk — medium: Organic Reddit buyer reports describe responsive WhatsApp service but shipping delays up to 7 weeks, tracking dead zones, and occasional Alibaba payment holds.